French pharma major Sanofi (Euronext: SAN) was trading 4% lower late Thursday after presenting its fourth quarter and full year 2023 financial results.
Sales for the fourth quarter grew by nearly 2% to 10.92 billion euros ($11.82 billion), while adjusted operating income fell 5% to 2.58 billion euros, where 2.77 billion euros had been forecast by analyts in a poll on the company's website.
"Our R&D transformation has reached an inflection point on the road to industry leadership in immunology"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze